Audentes Therapeutics Inc. is adding two new tools to its adeno-associated virus (AAV)-based gene therapy toolkit, enlisting expertise from Nationwide Children's Hospital and its own team to develop new vectorized antisense therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).